Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Myriad Genetics (MYGN) EPS (Weighted Average and Diluted) (2016 - 2025)

Historic EPS (Weighted Average and Diluted) for Myriad Genetics (MYGN) over the last 17 years, with Q3 2025 value amounting to -$0.29.

  • Myriad Genetics' EPS (Weighted Average and Diluted) fell 2083.33% to -$0.29 in Q3 2025 from the same period last year, while for Sep 2025 it was -$4.33, marking a year-over-year decrease of 23828.12%. This contributed to the annual value of -$1.41 for FY2024, which is 5581.52% up from last year.
  • Latest data reveals that Myriad Genetics reported EPS (Weighted Average and Diluted) of -$0.29 as of Q3 2025, which was down 2083.33% from -$3.57 recorded in Q2 2025.
  • In the past 5 years, Myriad Genetics' EPS (Weighted Average and Diluted) ranged from a high of $0.3 in Q3 2021 and a low of -$3.57 during Q2 2025
  • For the 5-year period, Myriad Genetics' EPS (Weighted Average and Diluted) averaged around -$0.54, with its median value being -$0.34 (2023).
  • As far as peak fluctuations go, Myriad Genetics' EPS (Weighted Average and Diluted) skyrocketed by 25000.0% in 2021, and later crashed by 77073.17% in 2025.
  • Quarter analysis of 5 years shows Myriad Genetics' EPS (Weighted Average and Diluted) stood at -$0.1 in 2021, then plummeted by 420.0% to -$0.52 in 2022, then surged by 34.62% to -$0.34 in 2023, then plummeted by 37.97% to -$0.47 in 2024, then surged by 38.18% to -$0.29 in 2025.
  • Its EPS (Weighted Average and Diluted) stands at -$0.29 for Q3 2025, versus -$3.57 for Q2 2025 and -$0.0 for Q1 2025.